Quality of life in stable and progressive 'early-stage' keratoconus patients
Standard
Quality of life in stable and progressive 'early-stage' keratoconus patients. / Steinberg, Johannes; Bußmann, Nils; Frings, Andreas; Katz, Toam; Druchkiv, Vasyl; Linke, Stephan J.
In: ACTA OPHTHALMOL, Vol. 99, No. 2, 03.2021, p. e196-e201.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Quality of life in stable and progressive 'early-stage' keratoconus patients
AU - Steinberg, Johannes
AU - Bußmann, Nils
AU - Frings, Andreas
AU - Katz, Toam
AU - Druchkiv, Vasyl
AU - Linke, Stephan J
N1 - © 2020 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.
PY - 2021/3
Y1 - 2021/3
N2 - PURPOSE: To analyse the vision-related quality of life (vr-QoL) in stable and progressive keratoconus (KC) patients with a still good visual acuity.METHODS: Combined prospective/cross-sectional study design. The Refractive Status and Vision Profile (RSVP) and the National Eye Institute Visual Functioning - 25 (NEI-25) questionnaire were used in 16 emmetropic, 32 myopic and 56 KC patients, whereby KC patients with a stable (n = 26) and patients with a progressive stage (n = 30) and some of them before and after corneal cross-linking (CXL; n = 10) were included. All patients had a DCVA in at least one eye of ≥0.7 (decimal chart).RESULTS: The analyses revealed a minor decline of the vr-QoL from emmetropes to myopes to early KC patients with a stable disease. Nonetheless, sociological subscales (i.e. 'social functioning', 'role difficulties' and 'dependency') did not display statistically significant differences comparing these groups. In progressive KC, we could demonstrate a statistically significant decline also of these sociological subscales, which did not improve after CXL.CONCLUSION: Due to a still high and almost unaffected vr-QoL in early KC patients and the distinct decline after progression without rehabilitation after CXL, a reconsideration of current strategies to perform CXL only after a progression is diagnosed should be re-evaluated.
AB - PURPOSE: To analyse the vision-related quality of life (vr-QoL) in stable and progressive keratoconus (KC) patients with a still good visual acuity.METHODS: Combined prospective/cross-sectional study design. The Refractive Status and Vision Profile (RSVP) and the National Eye Institute Visual Functioning - 25 (NEI-25) questionnaire were used in 16 emmetropic, 32 myopic and 56 KC patients, whereby KC patients with a stable (n = 26) and patients with a progressive stage (n = 30) and some of them before and after corneal cross-linking (CXL; n = 10) were included. All patients had a DCVA in at least one eye of ≥0.7 (decimal chart).RESULTS: The analyses revealed a minor decline of the vr-QoL from emmetropes to myopes to early KC patients with a stable disease. Nonetheless, sociological subscales (i.e. 'social functioning', 'role difficulties' and 'dependency') did not display statistically significant differences comparing these groups. In progressive KC, we could demonstrate a statistically significant decline also of these sociological subscales, which did not improve after CXL.CONCLUSION: Due to a still high and almost unaffected vr-QoL in early KC patients and the distinct decline after progression without rehabilitation after CXL, a reconsideration of current strategies to perform CXL only after a progression is diagnosed should be re-evaluated.
KW - Adult
KW - Collagen/therapeutic use
KW - Cornea/pathology
KW - Corneal Topography
KW - Cross-Linking Reagents/therapeutic use
KW - Cross-Sectional Studies
KW - Female
KW - Humans
KW - Keratoconus/diagnosis
KW - Male
KW - Photochemotherapy/methods
KW - Photosensitizing Agents/therapeutic use
KW - Prospective Studies
KW - Quality of Life
KW - Riboflavin/therapeutic use
KW - Visual Acuity
U2 - 10.1111/aos.14564
DO - 10.1111/aos.14564
M3 - SCORING: Journal article
C2 - 32914586
VL - 99
SP - e196-e201
JO - ACTA OPHTHALMOL
JF - ACTA OPHTHALMOL
SN - 1755-375X
IS - 2
ER -